Advances in the non-invasive assessment of metabolic dysfunction-associated steatotic liver disease
Metabolism and Target Organ Damage · 30.10.2026 · 6 (4)
DOI: 10.20517/mtod.2026.119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolism and Target Organ Damage, online erschienen am 30.10.2026. Verfasst von Ningrui Su und 2 weiteren Autor:innen. Die Arbeit nennt 78 Literaturangaben.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults worldwide. Liver biopsy remains the reference standard but is unsuitable for population-wide screening due to its invasiveness and cost. This review summarizes recent advances in non-invasive tests (NITs) for MASLD and proposes a conceptual three-tier framework to guide clinical practice. First-tier serum biomarker scores enable low-cost initial risk stratification in primary care. Second-tier imaging elastography techniques provide objective quantification of liver stiffness and steatosis for fibrosis staging. Third-tier emerging artificial intelligence (AI) and multi-modal integration models remain investigational but hold promise for precise subtyping. Despite substantial progress, challenges persist in accessibility, standardization, and cost-effectiveness. With the recent Food and Drug Administration (FDA) approvals of resmetirom and semaglutide for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis (F2-F3), and the acceptance of vibration-controlled transient elastography (VCTE) as a surrogate endpoint, NITs have become essential for patient selection, treatment monitoring, and longitudinal disease management. Future directions include multi-omics integration and AI-empowered clinical decision support, enabling a shift toward personalized, metabolic-driven care.
Zitieren
APA
Su, N., Zhou, D., & Fan, J. (2026). Advances in the non-invasive assessment of metabolic dysfunction-associated steatotic liver disease. Metabolism and Target Organ Damage, 6(4). https://doi.org/10.20517/mtod.2026.119
Vancouver
Su N, Zhou D, Fan J. Advances in the non-invasive assessment of metabolic dysfunction-associated steatotic liver disease. Metabolism and Target Organ Damage. 2026;6(4). doi:10.20517/mtod.2026.119
BibTeX
@article{Su2026,
author = {Su, Ningrui and Zhou, Da and Fan, Jiangao},
title = {Advances in the non-invasive assessment of metabolic dysfunction-associated steatotic liver disease},
journal = {Metabolism and Target Organ Damage},
year = {2026},
volume = {6},
number = {4},
doi = {10.20517/mtod.2026.119}
}
EUVIMED